Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
L. Kappos et al., Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial, NAT MED, 6(10), 2000, pp. 1176-1182
Citations number
41
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research General Topics
In this 'double-blind', randomized, placebo-controlled phase II trial, we c
ompared an altered peptide ligand of myelin basic protein with placebo, eva
luating their safety and influence on magnetic resonance imaging in relapsi
ng-remitting multiple sclerosis. A safety board suspended the trial because
of hypersensitivity reactions in 9% of the patients. There were no increas
es in either clinical relapses or in new enhancing lesions in any patient,
even those with hypersensitivity reactions. Secondary analysis of those pat
ients completing the study showed that the volume and number of enhancing l
esions were reduced at a dose of 5 mg. There was also a regulatory type 2 T
helper-cell response to altered peptide ligand that cross-reacted with the
native peptide.